See analyst estimates and all valuation multiples for Regenerative Medicine
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $118B | 10.3x | 36.4x | |
| $10.8B | 3.6x | 14.0x | |
| $3.9B | 12.3x | 29.8x | |
| $3.7B | 10.6x | 28.1x | |
| $3.6B | 90.7x | -7.8x | |
| $2.5B | 692.7x | -64.6x | |
| $2.2B | 3.8x | 33.9x | |
| $2.1B | 7.9x | 32.4x | |
| $1.5B | n/a | n/a | |
| $1.5B | 67.9x | -50.5x | |
| $1.1B | 18.8x | -2.6x | |
| $1.1B | 1819.9x | -43.9x | |
| $940M | 2.6x | 12.1x | |
| $872M | 15.4x | -1.9x | |
| $624M | 1.3x | 12.3x | |
| $582M | 2.9x | 26.3x | |
| $560M | 7.9x | 28.4x | |
| $471M | 16.7x | -2.9x | |
| $470M | n/a | n/a | |
| $431M | 12.1x | 24.5x | |
| $378M | 5.4x | -22.4x | |
| $347M | 85.4x | n/a | |
| $313M | 258.1x | n/a | |
| $288M | n/a | n/a | |
| $237M | 2456.2x | -1.4x | |
| $196M | 24.5x | -8.3x | |
| $186M | 0.6x | n/a | |
| $178M | 29.1x | -55.7x | |
| $170M | n/a | n/a | |
| $154M | 5.4x | 11.0x | |
| $132M | 1.1x | 17.9x | |
| $121M | 2.2x | 39.0x | |
| $119M | n/a | n/a | |
| $109M | 4.1x | -8.9x | |
| $91.6M | n/a | n/a | |
| $71.2M | n/a | -5.1x | |
| $59.3M | n/a | n/a | |
| $51.9M | 192.3x | -0.2x | |
| $48.3M | 35.1x | n/a | |
| $24.3M | n/a | n/a | |
| $23.0M | n/a | n/a | |
| $20.7M | 5.2x | n/a | |
| $16.8M | 21.8x | -3.5x | |
| $9.8M | 1.7x | n/a | |
| $9.5M | 4.6x | n/a | |
| -$161M | -2.7x | 0.8x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Regenerative Medicine